In particular, we focused on well-established (PD-L1, HER2, and vascular endothelial growth factor receptor 2 (VEGFR2)) and emerging (mesenchymal-epithelial transition (MET), fibroblast growth factor receptor 2 (FGFR2), Claudin 18.2 (CLDN18.2), and tumor-infiltrating lymphocytes (TIL)) biomarkers (Table 2). This evidence concerns the gene CD274 and neoplasm.